15:26 , May 9, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of miR-940, miR-451a, miR-16-5p and miR-17-3p could help predict response to Herceptin trastuzumab in HER2 (EGFR2; ErbB2; neu)-positive metastatic breast cancer patients. In 283 HER2-positive metastatic breast cancer patients receiving...
23:51 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Polycystic kidney disease (PKD) Studies in patient samples and mice suggest inhibiting miR-17 could help treat autosomal dominant polycystic kidney disease (ADPKD). In patient kidney samples, levels of miR-17 were higher than in samples...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-17-92 (miR-17-92) Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In a mouse model of medulloblastoma, miRNAs from the...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Retinoblastoma MicroRNA-17-92 (miR-17-92); miR-17; miR-20 Patient sample and mouse studies suggest inhibiting miRNAs encoded by the miR-17-92 cluster could help treat retinoblastoma. In patient samples,...